Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

@article{Tsang1991ComparisonOT,
  title={Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide},
  author={Lincoln L. H. Tsang and Charmaine Paulina Quarterman and Andreas J. Gescher and J. Andrew Slack},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1991},
  volume={27},
  pages={342-346}
}
The present study tested the hypothesis that the experimental antineoplastic imidazotetrazinone temozolomide degrades in the biophase to 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and exerts its cytotoxicity via this species. MTIC is a metabolite of the antimelanoma agent dacarbazine and is thought to be responsible for the antineoplastic activity of the latter. Cytotoxicity in vitro was investigated in TLX5 murine lymphoma cells. MTIC and temozolomide were cytotoxic in the absence… CONTINUE READING
BETA

Figures and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Similar Papers

Loading similar papers…